Targeting Bruton's tyrosine kinase in B cell malignancies

Rudi Hendriks, Saravanan Pillai, Laurens Kil

Research output: Contribution to journalArticleAcademicpeer-review

356 Citations (Scopus)

Abstract

Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies. Small-molecule inhibitors of BTK have shown antitumour activity in animal models and, recently, in clinical studies. High response rates were reported in patients with chronic lymphocytic leukaemia and mantle cell lymphoma. Remarkably, BTK inhibitors have molecular effects that cannot be explained by the classic role of BTK in BCR signalling. In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.
Original languageUndefined/Unknown
Pages (from-to)219-232
Number of pages14
JournalNature Reviews Cancer
Volume14
Issue number4
DOIs
Publication statusPublished - 2014

Cite this